Last reviewed · How we verify
Placebo for etoricoxib
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in clinical trials for etoricoxib efficacy evaluation.
At a glance
| Generic name | Placebo for etoricoxib |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—the psychological and physiological response to the expectation of treatment rather than any direct molecular action. In this context, it serves as the comparator for etoricoxib, a COX-2 selective inhibitor used for pain and inflammation.
Approved indications
- Control arm in clinical trials for etoricoxib efficacy evaluation
Common side effects
Key clinical trials
- The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168) (PHASE1, PHASE2)
- A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) (PHASE3)
- A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107) (PHASE3)
- Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil (PHASE3)
- PENG Block vs Intrathecal Morphine in Total Hip Arthroplasty (PHASE4)
- A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142) (PHASE4)
- Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1) (PHASE3)
- A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for etoricoxib CI brief — competitive landscape report
- Placebo for etoricoxib updates RSS · CI watch RSS
- Organon and Co portfolio CI